WallStreetZenWallStreetZen

NASDAQ: LBRX
Lb Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for LBRX

Based on 7 analysts offering 12 month price targets for Lb Pharmaceuticals Inc

Min Forecast
$35.00-13.22%
Avg Forecast
$58.14+44.17%
Max Forecast
$80.00+98.36%

Should I buy or sell LBRX stock?

Based on 7 analysts offering ratings for Lb Pharmaceuticals Inc.

Buy
Strong Buy
2 analysts 28.57%
Buy
4 analysts 57.14%
Hold
1 analysts 14.29%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although LBRX's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates LBRX as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their LBRX stock forecasts and price targets.

LBRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-10-09
lockedlocked$00.00+00.00%2026-10-06
lockedlocked$00.00+00.00%2026-10-05
lockedlocked$00.00+00.00%2026-10-02
lockedlocked$00.00+00.00%2026-08-24
BMO Capital
Bottom 17%
17
BuyMaintains$54.00+38.32%2026-08-12
Wolfe Research
Top 2%
99
BuyInitiates Coverage On$45.00+15.27%2026-07-07

1 of 1

Forecast return on equity

Is LBRX forecast to generate an efficient return?

Company
-50.56%
Industry
14.98%
Market
172.55%
LBRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is LBRX forecast to generate an efficient return on assets?

Company
-46.46%
Industry
21.21%
LBRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

LBRX earnings per share forecast

What is LBRX's earnings per share in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
-$5.82-4,255.29%
Avg 2 year Forecast
-$5.46-4,003.36%
Avg 3 year Forecast
-$5.03-3,694.29%

LBRX revenue forecast

What is LBRX's revenue in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$2.9M

LBRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LBRX$39.04$58.14+48.93%Buy
NKTR$36.95$125.75+240.32%Buy
AAPG$13.56$41.40+205.31%Strong Buy
TYRA$21.33$44.00+106.28%Buy
OMER$17.83$27.50+54.23%Strong Buy
View Top Biotech Stocks

Lb Pharmaceuticals Stock Forecast FAQ

Is Lb Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: LBRX) stock is to Buy LBRX stock.

Out of 7 analysts, 2 (28.57%) are recommending LBRX as a Strong Buy, 4 (57.14%) are recommending LBRX as a Buy, 1 (14.29%) are recommending LBRX as a Hold, 0 (0%) are recommending LBRX as a Sell, and 0 (0%) are recommending LBRX as a Strong Sell.

If you're new to stock investing, here's how to buy Lb Pharmaceuticals stock.

What is LBRX's earnings growth forecast for 2026-2028?

(NASDAQ: LBRX) Lb Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.68%.

Lb Pharmaceuticals's earnings in 2026 is -$85,685,000.On average, 14 Wall Street analysts forecast LBRX's earnings for 2026 to be -$187,664,525, with the lowest LBRX earnings forecast at -$216,555,842, and the highest LBRX earnings forecast at -$156,827,979. On average, 14 Wall Street analysts forecast LBRX's earnings for 2027 to be -$176,286,714, with the lowest LBRX earnings forecast at -$239,317,916, and the highest LBRX earnings forecast at -$127,359,223.

In 2028, LBRX is forecast to generate -$162,328,169 in earnings, with the lowest earnings forecast at -$231,414,418 and the highest earnings forecast at -$101,616,401.

What is LBRX's revenue growth forecast for 2026-2028?

(NASDAQ: LBRX) Lb Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.59%.

Lb Pharmaceuticals's revenue in 2026 is $0.On average, 14 Wall Street analysts forecast LBRX's revenue for 2026 to be $0, with the lowest LBRX revenue forecast at $0, and the highest LBRX revenue forecast at $0. On average, 14 Wall Street analysts forecast LBRX's revenue for 2027 to be $0, with the lowest LBRX revenue forecast at $0, and the highest LBRX revenue forecast at $0.

In 2028, LBRX is forecast to generate $92,132,204 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $663,893,822.

What is LBRX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: LBRX) forecast ROA is -46.46%, which is lower than the forecast US Biotechnology industry average of 21.67%.

What is LBRX's Price Target?

According to 7 Wall Street analysts that have issued a 1 year LBRX price target, the average LBRX price target is $58.14, with the highest LBRX stock price forecast at $80.00 and the lowest LBRX stock price forecast at $35.00.

On average, Wall Street analysts predict that Lb Pharmaceuticals's share price could reach $58.14 by Oct 9, 2027. The average Lb Pharmaceuticals stock price prediction forecasts a potential upside of 48.93% from the current LBRX share price of $39.04.

What is LBRX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: LBRX) Lb Pharmaceuticals's current Earnings Per Share (EPS) is $0.14. On average, analysts forecast that LBRX's EPS will be -$5.82 for 2026, with the lowest EPS forecast at -$6.71, and the highest EPS forecast at -$4.86. On average, analysts forecast that LBRX's EPS will be -$5.46 for 2027, with the lowest EPS forecast at -$7.42, and the highest EPS forecast at -$3.95. In 2028, LBRX's EPS is forecast to hit -$5.03 (min: -$7.17, max: -$3.15).

What is LBRX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: LBRX) forecast ROE is -50.56%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.